Are you interested in participating in a psychedelic clinical trial? Lots of studies are now enrolling heathy participants and individuals with specific health conditions. Search by psychedelic substance, location, health condition, and study status. Enroll today in psychedelic research trials!
You could be eligible to participate in a psychedelic clinical trial for research. Psychedelic studies in various stages, enroll both healthy volunteers and individuals with specific mental health conditions. Below is an up-to-date and searchable compilation of psychedelic clinical trials registered on clinicaltrials.gov.
When you find a study location in your area for a condition you have, contact the study sites through the listings in the clinical trial records provided below. You can also find more information about enrollment on clinical trial sponsors’ websites or clinical registry sites by country.
Psychedelic Clinical Trials Database
Browse our clinical trials database and filter by substance, location, condition, and enrollment status. Studies are displayed on a map and list.
Psychedelic Clinical Trial Forerunners
Research around the world is expanding quickly. New investigations for the therapeutic use of psychedelics, as well as inquiries into how the brain and consciousness works, are appearing all the time.
The forerunners in this field pave the way for others by contributing evidence-based findings to the body of knowledge. Several organizations, academic institutions, and corporations are leading the psychedelic clinical trial and research field forward. The Heffter Research Institute and the Beckley Foundation are pioneering non-profit organizations funding and supporting many dimensions of psychedelic research. The Usona Institute conducts pre-clinical and clinical research to further the understanding of the therapeutic effects of psilocybin and other consciousness-expanding medicines.
The Most Important Education You Didn’t Get In School.
You probably didn’t learn much in your formal education about therapeutic applications for psychedelics or how to reduce risks.
Start your learning journey now! Take our FREE COURSES.
Who Are the Leaders?
The Multidisciplinary Association for Psychedelic Studies (MAPS) is non-profit research and educational organization that develops medical, legal, and cultural contexts for people to benefit from the careful uses of psychedelics and marijuana. MAPS Public Benefit Corporation, a fully-owned subsidiary of MAPS, is sponsoring trials for MDMA-assisted psychotherapy for various anxiety-related conditions.
COMPASS Pathways is a mental health care company conducting psilocybin clinical trials in Europe and North America for treatment-resistant depression. The Imperial Centre for Psychedelic Research focuses on the mechanisms of action and clinical use of psychedelics, with a particular focus on researching treatments for depression. The Johns Hopkins University Center for Psychedelics & Consciousness Research researches how psychedelics affect behavior, mood, cognition, brain function, and biological markers of health. There are many more participating universities and organizations around the world.
How a Psychedelic Clinical Trial Works
A psychedelic clinical trial collects data to evaluate safety and efficacy of drugs under investigation in research. Drugs must pass through a sequence of phases or stages to become approved and available to patients.
A new substance is first thoroughly tested in human cells and/or animals to gain initial information about safety and toxicity. If enough research exists in scientific journals, sometimes an already known drug like some psychedelics, can go through less animal testing or wait till later in the process to complete.
After review, FDA can grant approval to test the drug in a small number of healthy individuals (phase 1). The next phase of testing involves giving a drug to people who have a disease or condition (phase 2) to evaluate safety and effectiveness to reduce symptoms.
Final Phases of Psychedelic Clinical Trial
If the drug appears safe and signals the potential to be a useful treatment, then a much larger number of people are tested in phase 3 trials at multiple study sites. For the Food and Drug Administration (FDA) to approve a new drug for a specific condition or disease, two phase 3 trials must show significant benefit that outweighs the risks or negative side effects of taking the drug.
After approval the drug is sold in the consumer market, research continues in phase 4 of the psychedelic clinical trial. This is known as post marketing surveillance trials. Phase 4 trials collect data on long-term effectiveness and safety. Finally, phase 4 also studies costs associated with treatment compared to other drugs in the market, and safety and effectiveness of the new drug versus other available treatment options.
This post was originally published in July 2018 and has evolved into an always current list and map.